Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Steffen-Sebastian Bolz_2023
VIEWPOINTS

Steffen-Sebastian Bolz, CSO of Aphaia Pharma Shares Insights from the P-II Study for Chronic Weight Management in Individuals with Obesity

Shots:  Steffen shared the details of the first patient enrolled in the P-II study of Aphaia Pharma’s lead product APH-012 to induce weight loss in individuals with obesity  He briefed the PharmaShots team about the study design of the P-II trial and also elaborated on the results from the P-I study The interview shows how…
February 27, 2023

Read more

VIEWPOINTS_Suresh Kannan_2023
VIEWPOINTS

Suresh Kannan, Chief Product Officer at Model N Shares Insights on the Fall 2022 Product Release of the Model N Revenue Cloud

Shots: Suresh Kannan discussed the latest semi-annual update to bring innovative revenue optimization and compliance solution for life sciences and high-tech innovators He elaborated on the Fall 2022 product release, providing customers with tools to improve automation, efficiency, and profitability during economic uncertainty along with streamlined pricing communication The interview gives an understanding of how…
February 16, 2023

Read more

VIEWPOINTS_Whitney Stewart_2023
VIEWPOINTS

Whitney Stewart, Director of Clinical Project Management at Curebase Shares Insights from the Release of a Publication with Digital Therapeutics Alliance

Shots:  Whitney gave a brief on the partnership of Curebase with Digital Therapeutics Alliance to provide fit-for-purpose evidence standard for DTx product regulatory, reimbursement, and clinical acceptance  Whitney also elaborated on the Fit-for-Purpose Evidentiary standards and talked about why  the DTx devices do not fit in the standards for medical devices by quoting some examples …
February 14, 2023

Read more

VIEWPOINTS_Nicolas Paquette-Lamontagne_2023
VIEWPOINTS

Nicolas Paquette-Lamontagne, VP, Medical Affairs at Blueprint Medicines Shares his Views on Clinical Data of Ayvakit for Patients with Systemic Mastocytosis

Shots:  Nicolas discussed about Systemic Mastocytosis as a disease and highlighted its epidemiology & other details. He also spoke about the clinical data of avapritinib presented at the ASH’22 Annual Meeting     Nicolas also shared the key findings from the PATHFINDER and EXPLORER trial evaluating avapritinib and the rationale behind conducting two different trials  This interview…
February 13, 2023

Read more

VIEWPOINTS_Dr. Philip M. Toleikis_2023
VIEWPOINTS

Dr. Philip M. Toleikis, President & CEO at Sernova Shares Insights on the Partnership with Evotec to Develop a ‘Functional Cure’ for Diabetes

Shots:  Dr. Philip shared his views on the collaboration of Sernova with Evotec for iPSC-Based Beta cell replacement therapy to develop and commercialize a ‘Functional Cure’ for diabetes.   He also gave an overview on the benefits of Evotec’s iPSC-based insulin-producing beta cells on the next generation of Sernova’s Cell Pouch System  The interview discusses about how Sernova…
February 7, 2023

Read more

VIEWPOINTS_Toni R. Hofhine_2023
VIEWPOINTS

Toni R. Hofhine, President of ATCOR Medical (CardieX) Shares Insights from Pulse- a New at-home Heart Health Monitor

Shots: Toni spoke about the CONNEQT Pulse the first dual blood pressure monitor with ATCOR’s SphygmoCor technology. The device is used for remote patient monitoring, home health, and clinical trials  She also elaborated about the data used for the pre-marketing submission with FDA. She explained the seven key vascular biomarkers that the device measures and…
February 6, 2023

Read more

VIEWPOINTS_John Gabrielson_2023
VIEWPOINTS

John Gabrielson SVP, Biosimilars & Head of Business of Similis Bio (JSR Life Sciences) Shares Insights on the Partnership with Blau Farmaceutica to Co-Develop Four Biosimilar Programs

Shots:  John spoke about the agreement between Similis Bio (a biosimilar partner and affiliate company of JSR) and Blau Farmaceutica to develop products and license IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders Under the collaboration, Similis Bio will provide full processes and associated IP for tech transfer to Blau…
February 2, 2023

Read more

VIEWPOINTS_Dr. Richard Philipson_2023
VIEWPOINTS

Dr. Richard Philipson, CMO at Calliditas Shares Results & Insights from P-III Study Evaluating Tarpeyo

Shots:  Dr. Richard talked about the results from the NefIgArd P-III trial evaluating Tarpeyo (Nefecon) for the treatment of IgA Nephropathy  He also highlighted the safety and efficacy results from the NefIgArd study. He also spoke more about Trapeyo and the roadmap for its global approval and commercialization  The interview shows up how Calliditas is…
January 9, 2023

Read more

VIEWPOINTS_Dr. Jeff Cleland_2023
VIEWPOINTS

Dr. Jeff Cleland, CEO & President at Ashvattha Therapeutics Shares his Views From First Patient Enrolled for the Treatment of AMD and DME

Shots: Jeff spoke about the first patient enrolled in a P-II study of D-4517.2 for the treatment of wet AMD and DME Jeff also talked about Ashvatta’s Hydroxyl Dendrimer Platform and how this technology is beneficial to treat AMD and DME The interview gives a profound understanding of how Ashvattha is developing hydroxyl dendrimer therapeutics…
January 3, 2023

Read more

Load more